New research reveals that people who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt conventional lifestyle programs.
Research printed in a prominent health publication demonstrates that while overweight individuals often shed substantial amounts of their total mass while on the medication, the mass comes back at an estimated rate of nearly a kilo each month after stopping.
"People buying these medications should be aware of the risk of fast rebound weight gain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to starting mass in about a year and a half.
Comparing Approaches
The study, which examined dozens of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that people who lose weight through dieting generally have a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Nutrition scientists believe the way of the injections accounts for the heightened regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Long-term administration of the hormone levels far above than the body's typical production might result in the system to produce less of its own natural hormone, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement means appetite is unsuppressed, making overeating much more probable."
A Chronic Issue?
Medical guidelines suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians say that, considering the likelihood of relapse, the treatment should be considered life-long.
This perspective is echoed by drug manufacturers, who note that the results "emphasize the chronic nature of excess weight," akin to managing conditions like high blood pressure.
User Experiences
Individuals who have discontinued the jabs report a intense resurgence of appetite.
"I experienced something activating and you're instantly extremely hungry," said a patient.
The struggle is compounded if users have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Use
Figures show that a significant number of people in the UK have used these injections in the past year, with demand being substantial.
- Use is more common among females than men.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and long-term success hinges on ongoing lifestyle management.
